VEGFA and neoplasm: In a recently published study [7], we showed that combined treatment of carbenoxolone with Bevacizumab (Avastin), an anti-vascular endothelial growth factor (VEGF) drug, prolonged the efficacy of the drug and resulted in a significantly lower tumor volume.